🔎 Trials Near Me

Home › Endometrial Cancer › Oklahoma

Endometrial Cancer clinical trials in Oklahoma

28 studies for Endometrial Cancer are looking for participants at sites in Oklahoma.

Cities in Oklahoma

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
All ages · All sexes · Updated Oct 2, 2026 · NCT05564377

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

  • University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 1
Ages 18 and older · Women · Updated Oct 2, 2026 · NCT05950464

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • University of Oklahoma, Oklahoma City
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

  • University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 3
Ages 18 and older · Women · Updated Oct 2, 2026 · NCT07198074

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

  • University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 28, 2026 · NCT05112601

Study of AVZO-021 in Patients With Advanced Solid Tumors

  • Avenzo Therapeutics Recruiting Site, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05867251

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

  • University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 24, 2026 · NCT05640999

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  • University of Oklahoma, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

  • Peggy & Charles Stephenson Oklahoma Cancer Center, Oklahoma City
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 17, 2026 · NCT06340568

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

  • OU Health Stephenson Cancer Center, Oklahoma City
RecruitingPhase 1
Ages 15 and older · All sexes · Updated Aug 25, 2026 · NCT06276491

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

  • Stephenson Cancer Center at OU Health, Oklahoma City
RecruitingPhase 2
Ages 18 and older · Women · Updated Aug 21, 2026 · NCT05548296

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

  • Normunity Investigational Site, Oklahoma City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07182149

A Study of DM002 in Patients With Advanced Solid Tumors

  • University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06751329

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • University of Oklahoma - Health Sciences Center, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05579366

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

  • Stephenson Cancer Center, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT04657068

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)

  • Mercy Hospital - OKC, Oklahoma City
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT07327489

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

  • Stephenson Cancer Center Oklahoma University Health, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT05377996

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

  • University of Oklahoma Health Stephenson Cancer Center, Oklahoma City
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Apr 1, 2026 · NCT04486352

Uterine Preservation Via Lifestyle Transformation

  • University of Oklahoma, Oklahoma City
RecruitingPhase 2
Ages 18 and older · Women · Updated Jan 20, 2026 · NCT05903131

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

  • Dren Investigational Site, Oklahoma City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jan 7, 2026 · NCT06999187

Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

  • University of Oklahoma, Oklahoma City
RecruitingPhase 1
Ages 18 and older · Women · Updated Dec 11, 2025 · NCT06795009

Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

  • Oklahoma University Stephenson Cancer Center, Oklahoma City
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 13, 2025 · NCT05997017

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

  • University of Oklahoma, Oklahoma City
RecruitingPhase 2
Ages 18 to 70 · Women · Updated Oct 30, 2025 · NCT06481592

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Tulsa
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

  • Oklahoma Cancer Specialists and Research Institute, Tulsa
RecruitingPhase 2/3
Ages 18 and older · Women · Updated May 2, 2024 · NCT05797831

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.